Biotechnology / Investing

Pharmaceutical firm Vaccinogen to move to Baltimore

The cancer treatment company, which just secured an $80 million investment, will move from Frederick in the next six months.

Vaccinogen CEO Andrew Tussing. (Photo courtesy of Vaccinogen)

Frederick, Md.-based pharmaceutical firm Vaccinogen will move to Baltimore following an $80 million round of funding, the Baltimore Business Journal reports.
On Monday, Vaccinogen officials announced the funding had been secured from a “Stockholm-based investor group known as The Investment Syndicate (‘TIS’).” Additionally, celebrated pediatric neurosurgeon Ben Carson was named chairman of the company’s board.
“We believe this level of financing is very significant and the market will be very receptive to us at this time as we go through rapid growth,” CEO Andrew L. Tussing told the BBJ.
The company has yet to identify its new home in Baltimore, which will host 25 employees, according to the BBJ report.
Officials said the city’s population of universities and biotech firms and proximity to BWI Airport were factors in the decision. Vaccinogen is currently testing OncoVAX, a treatment to prevent the recurrence of colon cancer.

Companies: Vaccinogen

Knowledge is power!

Subscribe for free today and stay up to date with news and tips you need to grow your career and connect with our vibrant tech community.


WeWork approached physical space as if it were virtual — which led to the company’s downfall

The Tech Behind: How Baltimore's Washington Monument gets lit every winter holiday

Download the inaugural State of the Baltimore Tech Economy Report

Baltimore, let’s celebrate: You picked these 5 winners for your 2023 Awards

Technically Media